Company Filing History:
Years Active: 2022
Title: The Innovative Mind of Stephan Weisz
Introduction
Stephan Weisz is a remarkable inventor based in Freising, Germany. With a focus on groundbreaking advancements in the field of biomedicine, he has contributed significantly to the development of fusion proteins, which hold tremendous potential for treating complex diseases.
Latest Patents
Stephan holds a patent for "Fusion proteins of PD-1 and 4-1BB." This invention pertains to fusion proteins that include an extracellular domain with a polypeptide derived from PD-1 or CD40L at the N-terminus, a transmembrane domain, and an intracellular domain containing a polypeptide from 4-1BB or CD28 at the C-terminus. He also envisions fusion proteins featuring CD28 at the N-terminus and CD40L at the C-terminus. The patent extends to nucleic acid molecules encoding these fusion proteins, vectors carrying the nucleic acids, and host cells containing such vectors. Moreover, it discusses methods for producing the host cells and the pharmaceutical compositions that comprise these fusion proteins, which are particularly useful in the treatment of diseases associated with PD-1/PD-L2 or CD40 binding, as well as PD-L1/PD-L2 or CD40 expression, including cancer and chronic viral infections.
Career Highlights
Stephan is affiliated with the Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), where he engages in cutting-edge research aimed at enhancing human health. His work in the domain of fusion proteins contributes to innovative approaches in therapeutic development.
Collaborations
Throughout his career, Stephan has collaborated with esteemed colleagues, including Elfriede Noessner and Ramona Schlenker. These partnerships have fostered an environment of creativity and teamwork, allowing for the exchange of ideas that drive their research forward.
Conclusion
Stephan Weisz's contributions to the field of biomedicine through his patent on fusion proteins mark him as a significant figure in innovation. His work plays a crucial role in advancing therapeutic options for serious diseases, highlighting the importance of ongoing research and collaboration in the scientific community.